-

01:18:44 AM

Latest MDNA Stock Market News

MDNA - Medicenna Therapeutics Corp

09/14/21 8:00 AM

Nasdaq : MDNA

clinical trial

Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study

Preliminary efficacy readouts from study expected over

RHEA-AI

neutral

09/09/21 9:00 AM

Nasdaq : MDNA

conferences

Medicenna Therapeutics to Present at Upcoming September Investor Conferences

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be

RHEA-AI

neutral

08/13/21 7:00 AM

Nasdaq : MDNA

earnings

Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights

Medicenna Therapeutics

RHEA-AI

very positive

08/04/21 9:00 AM

Nasdaq : MDNA

earnings

Medicenna to Announce First Quarter Fiscal 2022 Financial Results and Operational Highlights on Friday, August 13, 2021

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 13, 2021 at 8:30 AM ET to report

RHEA-AI

neutral

07/27/21 9:00 AM

Nasdaq : MDNA

clinical trial

Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference

- Phase 1/2 ABILITY Study is designed to evaluate MDNA11, a potentially best-in-class IL-2 Superkine, in patients with advanced solid tumors - Study to start enrollment in the third quarter of 2021 in Australia, with expansion to additional sites in the US, UK and Canada - Presentation by

RHEA-AI

neutral

07/14/21 9:00 AM

Nasdaq : MDNA

Medicenna’s IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer

The data highlight the ability of MDNA109 armed

RHEA-AI

positive

06/23/21 9:00 AM

Nasdaq : MDNA

clinical trial

Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11

Preliminary update on safety,

RHEA-AI

positive

05/28/21 7:30 AM

Nasdaq : MDNA

earnings

Medicenna Reports Fiscal Year 2021 Financial Results and Operational Highlights

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and

RHEA-AI

positive

05/20/21 9:00 AM

Nasdaq : MDNA

earnings

Medicenna to Announce Fiscal Year 2021 Financial Results and Operational Highlights on Friday, May 28, 2021

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on May 28, 2021 at 8:30 AM ET to report its

RHEA-AI

neutral

05/12/21 9:00 AM

Nasdaq : MDNA

management

Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Mann Muhsin, MD, as the Company’s Chief Medical Officer. “Mann’s expertise in

RHEA-AI

positive

MDNA Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.medicenna.com
Security nameMedicenna Therapeutics Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees2021
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

MDNA Description:

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna's long-acting IL2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna's lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.